Jifeng Feng

Jiangsu Cancer Hospital - Department of Medical Oncology

Nanjing

China

Nanjing Medical University - Jiangsu Institute of Cancer Research

Nanjing

China

Nanjing Medical University - Affiliated Cancer Hospital

Nanjing

China

SCHOLARLY PAPERS

5

DOWNLOADS

79

CITATIONS

1

Scholarly Papers (5)

1.

Pyrotinib or Lapatinib Combined with Capecitabine in Women with HER2-Positive Metastatic Breast Cancer Previously Treated with Taxanes, Anthracyclines, And/Or Trastuzumab: An Open-Label, Randomised, Phase 2 Study

Number of pages: 111 Posted: 22 Nov 2018
Chinese Academy of Medical Sciences - Department of Medical Oncology, Hunan Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital, Department of Medical OncologyChinese Academy of Medical Sciences - Peking Union Medical College, Jilin University (JLU), Faculty of Medical Sciences, First Affiliated Hospital, Academy of Military Medical Science, Tianjin Medical University, Hebei Medical University, Peking University - Cancer Hospital and Institute, Huazhong University of Science and Technology (Formerly Tongi Medical University), Jiangsu Cancer Hospital - Department of Medical Oncology, Sun Yat-Sen University (SYSU) - Cancer Center, Fudan University - Shanghai Cancer Center (FUSCC), Jiangsu Hengrui Medicine Co., Ltd. and Jiangsu Hengrui Medicine Co., Ltd.
Downloads 32 (452,354)

Abstract:

Loading...

Pyrotinib, lapatinib, HER2-positive metastatic breast cancer

2.

Nivolumab versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 078 Randomised Phase 3 Clinical Trial

Number of pages: 31 Posted: 25 Sep 2018
Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangdong Lung Cancer Institute, Department of Pulmonary Oncology, Shanghai Jiao Tong University (SJTU), Jilin Cancer Hospital, Tongji University, Chinese Academy of Sciences (CAS), The Chinese University of Hong Kong (CUHK), Sun Yat-Sen University (SYSU), Guangdong Academy of Medical Sciences, Hunan Cancer Hospital, Jiangsu Cancer Hospital - Department of Medical Oncology, Zhejiang Cancer Hospital, Leningrad Regional Clinical Hospital, Zhejiang University, Henan Cancer Hospital, Sichuan University - West China Hospital, Central South University, Chinese Academy of Medical Sciences - Peking Union Medical College, Bristol-Myers Squibb, Bristol-Myers Squibb and Fudan University
Downloads 28 (471,410)
Citation 1

Abstract:

Loading...

nivolumab; PD-1 inhibitor; non-small-cell lung cancer; NSCLC; China; docetaxel; immunotherapy

3.

Chidamide Plus Exemestane for Postmenopausal Patients with Hormone-Receptor-Positive Advanced Breast Cancer (ACE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial

Number of pages: 90 Posted: 05 Feb 2019
Chinese PLA General Hospital, Fifth Medical Centre, Jilin University (JLU), Faculty of Medical Sciences, First Affiliated Hospital, Fudan University - Shanghai Cancer Center (FUSCC), Harbin Medical University - Cancer Hospital, Liaoning Cancer Hospital & Institute, Henan Cancer Hospital, Sun Yat-Sen University (SYSU) - Cancer Center, Hunan Cancer Hospital, Jiangsu Province People's Hospital, Tumour Hospital of Hebei Province, Tianjin Medical University, Jilin Cancer Hospital, Anhui Provincial Hospital, Shandong University - Jinan Central Hospital, Third Hospital of Nanchang, Beijing Cancer Hospital, Anhui Medical University - First Affiliated Hospital, Jiangsu Cancer Hospital - Department of Medical Oncology, Zhejiang Cancer Hospital, Peking University - Shenzhen Hospital, Fudan University - Department of Medical Oncology, Cangzhou Central Hospital, Northwestern University - Feinberg School of Medicine, Chipscreen Biosciences Ltd and Chipscreen Biosciences Ltd
Downloads 14 (550,350)

Abstract:

Loading...

Chidamide; Histone deacetylase inhibitor; Exemestane; Hormonereceptor- positive; Advanced breast cancer; Phase 3 trial

4.

Randomized Controlled Trial of Irinotecan Plus S-1 for Pretreated Patients with Advanced Esophageal Squamous Cell Carcinoma

Number of pages: 66 Posted: 24 Sep 2018
Chinese Academy of Medical Sciences - Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital, Department of Medical OncologyChinese Academy of Medical Sciences - Peking Union Medical College, Henan Cancer Hospital, Chinese Academy of Medical Sciences - Peking Union Medical College, Xinxiang Medical University - First Affiliated Hospital, Tianjin Cancer Hospital, Hunan Cancer Hospital, Harbin Medical University - Cancer Hospital, Shandong University - Shandong Cancer Hospital, Jiangsu Cancer Hospital - Department of Medical Oncology, Jilin Cancer Hospital, Shanxi Cancer Hospital, Shanxi Cancer Hospital, Huazhong University of Science and Technology (Formerly Tongi Medical University) - Tongji Hospital, Chifeng Municipal Hospital, Central South University - Second Xiangya Hospital, Zhengzhou University - First Affiliated Hospital and Chinese Academy of Medical Sciences - Peking Union Medical College
Downloads 3 (621,266)

Abstract:

Loading...

Esophageal Squamous Cell Carcinoma; Irinotecan; S-1

5.

FOX-A1 Contributes to Acquisition of Chemoresistance in Human Lung Adenocarcinoma via Transactivation of SOX5

Number of pages: 53 Posted: 09 Apr 2019
Jiangsu Cancer Hospital - Department of Medical Oncology, Nanjing University - Medical School, Jiangsu Cancer Hospital - Department of Medical Oncology, Soochow University - Department of Medical Oncology, Wake Forest University - Institute for Regenerative Medicine, Jiangsu Cancer Hospital - Department of Medical Oncology, Nanjing University - Medical School, Soochow University - Department of Medical Oncology, Soochow University - Department of Medical Oncology and Jiangsu Cancer Hospital - Department of Medical Oncology
Downloads 2 (631,171)

Abstract:

Loading...

lung adenocarcinoma; chemoresistance; FOX-A1; SOX5